Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 3Sarcoma 1NET 1Head & Neck 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 28Neoplasms 4Melanoma 4Carcinoma, Neuroendocrine 4Sarcoma 3Pheochromocytoma 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Liver Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Carcinoid Tumor 3Breast Neoplasms 3Thyroid Neoplasms 2Thymus Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Paraganglioma 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2Multiple Myeloma 2Meningioma 2Lung Neoplasms 2Insulinoma 2Head and Neck Neoplasms 2

Interventions

repotrectinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Intestinal Neoplasms × NET × 30 days × Clear all
NCT03093116 2026-05-27

TRIDENT-1

Turning Point Therapeutics, Inc.

Phase 1/2 Recruiting
500 enrolled 2 FDA
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Neuroectodermal Tumors, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡